Selenium (selenium)

It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Supplied as a pharmacy bulk package or single-dose vial for admixing use only. Not for direct IV infusion. Prior to administration, selenious acid injection must be transferred to a separate parenteral nutrition container, prepared and used as an admixture in parenteral nutrition solutions.

The final parenteral nutrition solution is for IV infusion into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsmol/L or greater must be infused through a central venous catheter.

The dosage of the final parenteral nutrition containing selenious acid injection must be based on the concentrations of all components in the solution and the recommended daily nutritional requirements. Consult the prescribing information of all added components to determine the recommended nutritional requirements for dextrose, amino acids and lipid emulsion, as applicable.

There are two dosage strengths for selenious acid injection: 6 mcg/mL and 60 mcg/mL of selenium. Selenious acid injection in a concentration of 6 mcg/mL is recommended for use in pediatric patients, particularly those weighing 7 kg or less.

Monitor selenium concentrations during treatment.

See full prescribing information for additional information on preparation, administration, and general dosing considerations.

The following dosage is a general recommendation intended for most pediatric patients. However, based upon clinical requirements, some patients may require a higher dosage.

Recommended Dosage in Pediatric Patients 7 kg and above: 2 mcg/kg/day (up to 60 mcg/day).

Recommended Dosage in Pediatric Patients less than 7 kg: 2 to 4 mcg/kg/day.

Dosage should be individualized based on the patient's clinical condition, nutritional requirements, and the contribution of oral or enteral selenium intake.

The following dosage is a general recommendation intended for most adults. However, based upon clinical requirements, some patients may require a higher dosage.

Recommended Dosage in Adults: 60 mcg/day.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

None.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

No selenium-related adverse reactions in patients receiving IV administered parenteral nutrition solutions containing selenious acid within the recommended dosage range.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

Selenious acid injection is approved for use in the pediatric population, including neonates, as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Safety and dosing recommendations in pediatric patients are based on clinical experience.

Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with selenious acid injection may be at higher risk of aluminum toxicity.

Administration of the recommended dose of selenious acid injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with IV selenious acid.

The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Deficiency of trace elements, including selenium, is associated with adverse pregnancy and fetal outcomes. Pregnant women have an increased metabolic demand for trace elements, including selenium. Parenteral nutrition with selenium should be considered if a pregnant woman's nutritional requirements cannot be fulfilled by oral or enteral intake.

Selenium is present in human milk. Administration of the approved recommended dose of selenious acid injection in parenteral nutrition is not expected to cause harm to a breastfed infant. There is no information on the effects of selenious acid on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for selenious acid and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition.

Reported clinical experience with IV selenious acid has not identified a difference in selenium requirements between elderly and younger patients. In general, dose selection should be individualized based on the patient's clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.